Breaking Canadian GLP-1 news
GLP-1 News
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Where are you in your GLP-1 journey?
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Canada Positioned as Global Test Market for Generic Semaglutide
Sandoz now expects Canada's generic semaglutide market to take shape in Q3 2026, with policy-driven list price cuts of about 65% once three competitors arrive.
Hims & Hers Expands Canadian Generic Semaglutide at $149/Month
Hims & Hers is expanding generic semaglutide access in Canada via telehealth starting at CAD $149/month, following Health Canada's first G7 generic authorization.
Canadian Benefits Plans Face GLP-1 Strategy Reckoning in 2026
Canadian employer plans face converging 2026 pressures: Ozempic now drives $807M in public drug spend as generics arrive and tirzepatide stays brand-priced.
Health Canada's 73% Initial-Rejection Rate Shapes Generic Queue
Health Canada issued notices of non-compliance on 73% of generic submissions in 2024-25, a pattern now visible across the semaglutide applicant queue.
Canada Patient Costs Drop as Generic Semaglutide Reaches Pharmacies
BBC reports Canada is the first G7 country to approve a generic semaglutide injection, with patient out-of-pocket costs falling to under a third of brand pricing.
Hers Canada Lists Apotex Generic Semaglutide on Telehealth Platform
Hers Canada is now listing Apotex-manufactured generic semaglutide on its telehealth platform, following Health Canada's April 2026 generic authorization.
PCPA Tiered Framework Sets the Pace for Canadian Generic Semaglutide Price Cuts
Canadian generic semaglutide pricing follows a PCPA tiered schedule; experts say three authorized generics are needed before monthly costs approach $100.
Seven Generic Semaglutide Files Remain in Health Canada Queue
After authorizing Apotex as the second generic semaglutide in Canada, Health Canada still has seven other submissions under active review as of October 2026.
Pharmacist Substitution Rules Shape Canada's Generic Semaglutide Rollout
Canadian pharmacists can substitute the Dr. Reddy's generic semaglutide authorized April 28, 2026 without a new prescription in most provinces, pending stocking.
Novo, Lilly Executives Flag Canadian Generic Supply Constraints
Novo Nordisk and Eli Lilly executives told investors Canadian generic entrants face supply constraints while savings cards defend brand volume in cash channels.
Canada Counterfeit GLP-1 Advisory Meets Generic Supply Gaps
Health Canada advisory RA-81518 warns of unauthorized GLP-1 products as Lilly and Novo Nordisk cite Canadian generic supply constraints in Q2 earnings calls.
Dr. Reddy's, Apotex Eye Global Export of Canada-Approved Generics
Dr. Reddy's has filed for generic semaglutide approval in 80+ countries and Apotex holds tentative FDA approval, using Canada as its first launch market.
Health Canada Warns on Counterfeit GLP-1s as Generic Supply Tightens
Health Canada advisory RA-81518 warns against unauthorized GLP-1 products as Eli Lilly flags significant generic supply constraints in the Canadian market.
TrumpRx US GLP-1 Deal Sets $245 Floor as Canada Awaits Generics
TrumpRx will phase GLP-1 prices from US$350 to US$245 by 2028, but Canadian pharmacy prices already sit lower as generic semaglutide arrives.
Novo Nordisk Aligns Ozempic Price With Generics as Apotex Ships
Novo Nordisk cut Ozempic pricing for uninsured Canadians via a savings card as Apotex began shipping generic semaglutide and Dr. Reddy's expanded distribution.
Health Canada Warns of Counterfeit Ozempic, Mounjaro Sellers
Health Canada advisory RA-81518 flags unauthorized and counterfeit GLP-1 products sold by retailers and online, urging purchases only from licensed pharmacies.
Eight Generic Semaglutide Files Still Under Health Canada Review
Health Canada is reviewing eight additional generic semaglutide submissions after Dr. Reddy's April 28 authorization, with Apotex offering full SKU parity to Ozempic.
Lilly Q2 Mounjaro Sales Hit US$9.94B as Canada Generics Emerge
Eli Lilly reported US$9.94B in Q2 Mounjaro sales as executives flagged Canadian generic supply constraints and Novo Nordisk defended volumes via savings cards.
Lilly, Novo Cite Canadian Generic Competition in Q2 Earnings
Novo Nordisk and Eli Lilly executives addressed Canadian generic competition in Q2 earnings calls, citing savings cards and supply constraints among generic entrants.
BMJ: Canada Second Country Globally to Approve Generic Semaglutide
BMJ reports Canada is only the second country worldwide to approve generic semaglutide, following Health Canada nods to Dr. Reddy's and Apotex.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada